Mild-to-moderate dementia Nervous System Diseases Dementia
Conditions
Interventions
This intervention is for community-dwelling patients with memory problems in Northern Ireland and will be held within a community pharmacy. The intervention consists of two parts, which are completed
Sponsors
Queen's University Belfast
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Community pharmacist participants: 1. Located in Northern Ireland 2. Access to a private consultation room Patient participants: 1. A formal diagnosis of mild-to-moderate dementia (confirmed by their GP) 2. Prescribed four or more regular medications (excluding medications prescribed to be taken or used only when required) 3. Have at least 12 months’ dispensing data available on the pharmacy patient medication record from the time of screening 4. Live in their own home 5. Have a carer Carer participants: 1. Have contact with the patient at least three times a week 2. Assist the patient with their medicines
Exclusion criteria
Exclusion criteria: Those who cannot provide written informed consent
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1. The usability and acceptability of the intervention will be assessed through qualitative face-to-face interviews with pharmacists, patients and their carers. These interviews will enable us to find out about their experiences of taking part as well as identifying any ways in which the intervention could be improved. Interviews with pharmacists will take place 2 weeks after all medication reviews are completed with recruited patients and carers. Interviews with patients and their carers will be conducted 2 weeks after they have attended the medication review and adherence check. 2. The feasibility of recruitment procedures will be assessed by collecting the following data throughout the course of study, and final calculations which will be conducted at the end of the study: 2.1.The number of pharmacists approached, recruited and consented 2.2.The number of patients/carers screened, approached, recruited and consented 2.3. Patient retention rates. | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Feasibility of data collection procedures will be assessed by collecting data via questionnaires on the patient’s ability to take their prescribed medications, quality of life, behavioural and psychological symptoms of dementia and treatment burden. This data will be collected on the day that the patient and carer attend the review appointment and again, 4 weeks after the review has taken place. 2. The appropriateness of the medicines that the patient is prescribed will be assessed using data from pharmacy-held Patient Medication Records | — |
Countries
United Kingdom
Outcome results
None listed